• Contact
  • +31 (0)30 800 4800
  • nl | en
  • Home
  • About BBio
    • Our story
    • How it started
    • Science park
    • Together with
  • What we produce
    • Product overview
    • How we do it
    • Report side effects
  • Look inside
    • Projects
    • News
  • Contact
+31 (0)30 800 4800
nl | en



How it started

Bilthoven Biologicals emerged after privatizing NVI, formerly part of RIVM. The Cyrus Poonawalla Group acquired the vaccine producing part of NVI in 2012 and founded Bilthoven Biologicals.

Our history

We originated from the National Institute for Public Health and the Environment (RIVM). Here the development and production of vaccines started. In 2003, the activities for the national vaccination programme were continued under the name Dutch Vaccine Institute (NVI). An estimated 30% of vaccines produced globally are made with technology developed in Bilthoven.

Cyrus Poonawalla Group

Bilthoven Biologicals (BBio) originated after privatizing NVI. The Cyrus Poonawalla Group acquired the vaccine producing part of NVI and founded BBio. This resulted in a powerful combination of knowledge, network and facilities we employ daily to achieve our ambitions.

Dr. Cyrus Poonawalla  is CEO of the Cyrus Poonawalla group. He built Serum Institute of India, a successful vaccine conglomerate which is the world’s largest vaccine producer in sheer volume. He learned his trade at USPB, then called Antonie van Leeuwenhoek site.

In the 1970’s, the Dutch government took part in an exchange programme, inviting students from developing nations to learn how to develop vaccines. This way, we achieved using this  knowledge by developing nations.

Dr. Poonawalla made his company Serum Institute of India (SII) into a vaccine conglomerate. He bought the production part of the Dutch Vaccine Institute (NVI) in 2012, resulting in Bilhoven Biologicals. The acquisition of BBio resulted in a massive increase in production of polio vaccines. This contributes greatly to the effort to eradicate polio globally!

Our partners

  • About BBio
  • Look inside
  • Contact
Our vaccines
  • BCG
  • Tetanus vaccine
  • Combination DT-IPV vaccine
  • Poliomyelitis vaccine (IPV)
  • Report side effects
Latest vacancies
  • (Senior) EHS Officer
  • Senior Supervisor QC Microbiologie
  • Business Controller
  • Validation Engineer
Contact
Visiting address
Antonie van Leeuwenhoeklaan 13
3721 MA Bilthoven

+31 (0)30 800 4800
info@bbio.nl
Travel directions
© 2023 Bilthoven Biologicals
Manage cookie consent
To give you the best experience with our website, we use technologies such as cookies to store and/or access information about your device and your website use. If you do not give permission or withdraw your permission, certain functions and options on our website will not work for you.

Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service expressly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that have not been requested by the subscriber or user.
Statistics

The technical storage or access used solely for statistical purposes.
The technical storage or access used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance by your Internet Service Provider, or additional information from a third party, information stored or retrieved solely for this purpose generally cannot be used to identify you.
Marketing
The technical storage or access is necessary to create user profiles for sending advertising, or to track the user on a website or across different websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}